• Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine
• The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program
• Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://ibn.fm/I2lX7). The success of this study adds to Mydecine’s library of patent-pending tryptamines while also building upon the company’s strategy to enhance the safety and efficacy of its drug development candidates for both medical use and therapy. Mydecine has been a biotechnology and digital tech pioneer, pushing boundaries with its AI-driven drug discovery program. The integration of AI technology, which is currently done in partnership with Applied Pharmaceutical Innovation (“API”) at the University of Alberta, has accelerated the company’s natural product research and novel drug design. This move has also allowed it to scale much faster than would have been possible had Mydecine opted for traditional research methods. Dr. Khaled Barakat, the Principal Investigator at API and University of Alberta Associate Professor, noted, “Our AI technologies construct billions of new drug candidates and filter them for their ability to modulate the activity of the psychedelic-related targets. These AI models also predict the interactions and affinity of each drug candidate to the level of a single atom.” “By considering the unique structural and dynamical fingerprint of each target, our AI-drug discovery program paves the road towards designing selective modulators, hence, reducing any potential side effects that may emerge in the future,” he added. Mydecine’s addition of this compound has demonstrated the company’s ability to achieve proven principles of drug chemistry, time course of action, improved delivery, and compound stability. More importantly, the technology has helped with the effective production of an extensive base of preclinical, in vitro data which is integral to the company’s expansion of its drug pipeline. While making the announcement, Rob Roscow, Mydecine’s Chief Scientific Officer (“CSO”), noted, “Our ability to rapidly uncover safer and more efficacious novel compounds, such as this psilocin analogue, is a true testament to the value and success of our AI-driven drug discovery program. As we progress forward, we see great value from this development as we can now leverage the achieved receptor binding data for serotonin receptor (5-HT2A) and expand our drug pipeline focusing on the agonistic activity of psilocin and other tryptamines at different ratios on serotonin receptors.” Since it was founded in 2020, Mydecine has operated on the guiding principle that there is a significant unmet need and lack of innovations within the therapeutic and mental health environments. Through technology, the company hopes to remedy this situation. This recent milestone demonstrates what the company can do and the fact that there are potential psychedelic-based solutions for mental health and addiction. Mydecine will share this and other achievements at this year’s Wonderland Miami event, scheduled for November 8-9, an event dubbed as the largest psychedelic medicine business event ever put together (https://ibn.fm/b1YEZ). The event will be held at the Adrienne Arsht Center for the Performing Arts in Miami, Florida, and Mydecine expects to share its technological advancements, recent discoveries, and goals. For more information about the event, please visit the event’s website at www.microdose.buzz/wonderland/miami For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• American Gaming Association’s Gaming CEO Outlook expects industry growth in 2020 driven by new hiring, wage growth, and capital investment
• PLGNF sees explosive growth in October 2021 with a 1500% betting handle increase, and betting turnover reached approximately $1.6 million per day from $53,500 for September
• PLGNF’s IP-protected iGaming software solutions include Live Dealer Casino, E-Table Games, Daily Fantasy Sports
• PLGNF applications run securely on any browser without app store download, do not require sharing sensitive data

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market, is experiencing exponential growth with a 1500% betting handle increase in October (https://ibn.fm/zADPz), well ahead of optimistic predictions published by the American Gaming Association (“AGA”) in a recent report (https://ibn.fm/Kb7Ns). “We are a more resilient industry because of the COVID-19 pandemic,” said Aristocrat Technologies CEO and AGA Chairman Trevor Croker. “As the gaming industry looks to 2022 and beyond, our impressive recovery will continue to create jobs, support communities, and generate needed taxes.” The AGA is the premier national trade group representing the $261 billion U.S. casino industry, supporting 1.8 million jobs across the United States. The group’s newly published Gaming CEO Outlook suggests bullish industry confidence across the industry, with nearly half of AGA-member CEOs expecting improved 2022 business conditions, driven by expected increases in new hiring (71%), wage growth (63%), and capital investment (39%). “AGA’s inaugural Gaming CEO Outlook reflects the strength of our recovery and consumer demand for our world-class entertainment offerings,” said Bill Miller, AGA president and CEO. “The promising outlook is built on our innovation.” PLGNF leads this innovative change with its multi-tenant gateway that enables online operators to offer users iGaming software solutions, including Live Dealer Casino, E-Table Games, and Daily Fantasy Sports. With privacy in focus, PLGNF’s technology allows customers to access the platform without sharing sensitive data while offering seamless integration at the operator level. Fast and secure, PLGNF’s games run fast on all browsers and devices like any native application without requiring an app store download. “We knew our proprietary technology was innovative, however the reception we have received from our partners and clients has been unparalleled,” said Darcy Krogh, CEO of Playgon Games. “This is noticeable from the player wagering activity, which has increased to 305,000 bets for the half-month of October compared to 132,000 bets for the entire month of September. We are witnessing at least 100% growth across all of our key indicators. PLGNF’s management team brings over three decades of iGaming experience to the industry, with multiple successful exits. With a focus on delivering a first-class gaming experience to this generation of mobile-first gaming enthusiasts, PLGNF is positioned to lead the hyper-growth iGaming market due to high entry barriers and a valuable portfolio of IP-protected assets. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial
• The trial is set to commence in 2022, subject to a favorable review by the FDA
• The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase 2a clinical trial that explores psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. While making the announcement, Greg McKee, the Chairman and Chief Executive Officer of Tryp, noted, “We have been working diligently to complete this IND submission and are eager to initiate what will be one of the first evaluations of psilocybin to treat fibromyalgia in a Phase 2 study,” (https://ibn.fm/KVqCt). This trial is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D. from the university. It will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of co-morbidities that include, but are not limited to anxiety, depression, and poor sleep quality. Since its inception, Tryp has aimed to lead the next wave of psychedelic drug development, pushing beyond mental health. Its focus on psilocybin-based treatments for chronic pain and other indications has proven useful and highly effective. With this specific study, the company seeks to offer a more effective fibromyalgia solution than those that are currently available in the market today. It also aims to provide a long lasting solution with fewer side effects, ultimately affording patients better treatment for their condition. “Many fibromyalgia patients find insufficient relief from the currently available, FDA-approved treatments for the disease due to their limited efficacy and significant side effects. We have an opportunity with Tryp to conduct a Phase 2a study that evaluates the safety and clinical utility of psilocybin for fibromyalgia as we target the origins of the disease rather than simply treating patient symptoms,” noted Dr. Boehnke. Research has shown that the administration of psilocybin increases neuroplasticity while also addressing disrupted neural connections that are typically associated with fibromyalgia and other nociplastic pain indications. This Phase 2a study will seek to capitalize on that, starting with the administration of TRP-8802, coupled with psychotherapy. The study is expected to commence in 2022, subject to a favorable review of the IND by the FDA. “Through our close collaboration with Dr. Boehnke and other experts in the space, we have an appreciation of the limitations of current treatments for this disease and a determination to develop a more effective therapy for the millions of patients suffering from fibromyalgia,” noted Mr. McKee. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• The distribution component unlocks a new revenue source for the company, helping drive future growth
• MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain
• Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it
• MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the proprietary technology and platform.

A recent non-binding Letter of Intent (“LOI”) was signed between Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, and Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM. This is MINDCURE’s first international partnership with industry leaders developing rigorous psychedelics protocols and drugs that can be distributed through the company’s platform to support both therapists and patients. As well as distributing its partners’ protocols, the company will also be distributing its own protocols through iSTRYM. With the minimum viable product (“MVP”) version of iSTRYM already released into partner clinics across North America, the company expects to partner with 75 clinics in both Canada and the U.S. when beginning full commercia deployment in early 2022, and to double that number by Q4 2022. The distribution component of iSTRYM opens up a new source of revenue for the company, which will help fuel further growth and expansion strategies. MINDCURE’s digital therapeutics (“DTx”) platform was built to be scaled at a global level as a drug-agnostic digital tool and distribution platform. The company’s own protocols of ketamine for depression and ketamine for pain have already been created, with ketamine for an undisclosed indication currently in development. With additional revenue to drive growth goals, the company expects to be able to leverage multiple emerging opportunities on the fast-growing digital therapeutics market. Globally, the digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021, at a CAGR of 31.4% (https://ibn.fm/ARbYX). DTx is a subdivision of digital health, but not all digital health solutions are DTx. According to the Digital Therapeutics Alliance, DTx deliver evidence-based therapeutic interventions that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies, to optimize patient care and health outcomes. The rise in DTx can be attributed to the mass use of smart devices by consumers. Another element that has driven the demand for digital therapies has been the COVID-19 pandemic, with its associated stressors and increase in mental health conditions. A variety of segments stand to benefit from DTx and MINDCURE’s proprietary platform – therapists, patients, payers, and drug and protocol developers. Each segment has its own value proposition, according to the company:

• Therapist Value Proposition:

• Cost reduction
• More favorable outcomes
• An increased portfolio of protocols that can expand guidance on practice and payer code guidance
• Patient Value Proposition
  • Improved compliance
  • Outcomes are optimized
  • Proofing of the safety and efficacy
• Payer Value Proposition
  • Access to cumulative data on the patient outcomes and compliance
• Drug and Protocol Developer Value Proposition
  • A partner for distribution and sales
  • Provide line-of-sight to compliance; de-risk new protocol deployment

For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• The case study based on ShamirMuzik and his journey will serve as a means of showing how Fan Pass can help increase artist reach, revenue, and visibility
• The platform’s November contest can earn artists up to $175 ($150 for streaming + $25 for Instagram promotion) by performing live five times during the month
• Fan Pass has released its first fall merchandise line, with a limited time offering consisting of ten new designs donning over 20 new color choices

Mobile technology and marketing company Friendable (OTC: FDBL) announced the addition of ShamirMuzik to the company’s Fan Pass Live Streaming artist platform (https://ibn.fm/y6S4p). An affiliate of Warner Bros. Entertainment and currently part of independent label ‘The MHZ,’ ShamirMuzik brings along his existing fan base, social media followers, streams and an existing, robust connection with his audience. The artist has already achieved over 1 million streams each on YouTube and Spotify, with features on Netflix, VH1, Power 105.1, MTV and more. “I am very excited to embark on my journey with Fan Pass. They are a great platform for artists to utilize, especially when it comes to connecting with your fan base and supporters,” ShamirMuzik said. “I’m encouraging artists to jump on board because this is the future of a new wave that nobody has seen yet.” The company is working on a case study that revolves around every step of ShamirMuzik’s journey with the platform, showing examples of how artists can utilize the Pro Services offering to enhance the livestream experience with their own custom merchandise, eCommerce store, ticket sales, and more. The case study on ShamirMuzik will run through the end of the year and will serve as a way for Friendable to share the artist journey and how Fan Pass can help to extend reach, revenue, and visibility. ShamirMuzik currently has:

• Spotify – 1 million+ streams
• YouTube – 1 million+ streams
• Instagram – 114,000+ followers
• YouTube – 4,800+ followers and 1.4 million+ video views
• Twitter – 1,200+ followers

“Artists telling other artists about their experience, sharing with fans and allowing our team to share a case study that maps the next 60 days of Shamir’s journey with our platform, company and team is huge,” Friendable CEO Robert A. Rositano Jr. said. “We believe this is an important step as we seek expansion of our platform, services and artist database in the coming months as well.” Fan Pass offers Pro Services to artists and musicians who want to build a brand, attract more fans, and earn more income as a musician with quality logo graphics and merchandise designs. Pro Services come in three categories – Artist/Band Logo Design, Merch Designs, and Marketing Materials. Each of these categories is broken down into three tiers of pricing/product availability.

• Artist/Band Logo Design

• Basic – $50 – A single high-resolution design placed on one item
• Standard – $75 – Three high-resolution designs placed on three items
• Custom (25% off) – $110 – Five high-resolution designs placed on three items
• Merch Designs
  • Basic – $100 – Single high-resolution design (on a t-shirt in your store)
  • Standard – $275 – Three high-resolution designs (two t-shirts, one hoodie)
  • Pro (25% off) – $500 – Five high-resolution designs (placed on any five merch items available)
• Marketing Materials
  • Basic – $45 – Social Ad/Announcement designs to promote the next three events
  • Standard – $65 – Social Ad/Announcement designs to promote next five events
  • Premium (25% off) – $100 – The Standard Package, plus two merch ad designs to market the collection on social media

To begin the process, artists fill out the online form that gathers information about themselves or their musical group, including colors and styles they like. Next, Fan Pass designers create image designs for approval or revision requests. Once approved, the final graphics files are sent to the artist. Meanwhile, the company announced plans to increase the number of live performances given by the artists on the Fan Pass platform through a unique promotion that has been posted on the company’s Instagram page (https://ibn.fm/Npfl9). The headline is “Go Live, Earn $150!” Artists on the platform who go live in November can earn cash prizes every time they put on live performances (up to $150 plus an additional incentive). To be eligible to participate in the November contest, artists must stream their first event by Monday, November 8. Artists earn a cash prize with each stream during the month:

• Go Live 1X = $10
• Go Live 2X = $20
• Go Live 3X = $30
• Go Live 4X = $40
• Go Live 5X = $50

Altogether, these total the $150 cash prize for completing the streams during the month. Those artists who promote all five of their streams on Instagram and tag @fanpasslive earn an additional $25, bringing the earnings potential to $175. The Fan Pass platform also released its first-ever fall merchandise line in late October (https://ibn.fm/cplJ6). The new line is available for a limited time and features ten new products and over 20 new colors. Product pricing begins at $25 and up, offering shirts, hats, hoodies, and more. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• The Cannabis World Congress & Business Exposition (CWCBExpo) will be held in New York between November 4-6, 2021
• The conference will feature over 50 expert speakers, in addition to hundreds of exhibitors showcasing the sector’s latest product innovations
• Recent forecasts have estimated overall US marijuana retail sales to rise from $20 billion in 2020 to $38.4-45.9 billion by 2025

The Cannabis World Congress & Business Exposition (“CWCBExpo”) event is set to be held at New York City’s Javits Convention Center, Hall 3A between 4-6 November 2021. Set to be held during Cannabis Week, a weeklong event taking place between Monday November 1 – Sunday November 7, the CWCBExpo is a business-to-business trade show event dedicated to the legalized cannabis industry. The CWCBExpo has rapidly earnt a reputation as a leading forum for dispensary owners, growers, suppliers, investors, medical professionals, government regulators, legal counsel, and entrepreneurs looking to achieve business success and identify new areas of growth in this dynamic and fast-growing industry. Following a big 2020, during which cannabis sales increased by 48 percent, or $6.9 billion, the highest dollar increase in U.S. industry history, 2021 has thus far benefitted from strong sales momentum across a number of states. Mature markets such as Colorado, Oregon and Washington state have averaged 26% year-over-year growth over the first half of this year; meanwhile, states which have recently decriminalized cannabis usage, such as Illinois, Massachusetts, Michigan and Pennsylvania are witnessing sales growth of upwards of 136% – albeit, from a low base (https://ibn.fm/hegWP). With seven states set to potentially pursue legislation in the coming years which will legalize the recreational use of cannabis – including the likes of Ohio, Missouri, South Dakota, Oklahoma, North Dakota, Maryland and Arkansas, the upcoming CWCBExpo will seek to harness on the recent growth trends through a series of presentations, keynote addresses and case studies spanning a wide array of topics. The conference will be segmented into three daily themes – covering ‘Where We Are Today’, ‘Challenges & Solutions’ and ‘What’s Next?’, respectively. Topics which will be covered include:

• Industry Update: Data, Highlights, Trends and Opportunities
• New York: From Illicit into the Light
• International Cannabis: Delivering the Infrastructure to Enable Worldwide Markets
• Opportunities at the Intersection of Hemp and Marijuana

A full list of the presentation topics to be covered over the three-day event can be found at: https://s23.a2zinc.net/clients/leexpos/cwcbexpony2021/Public/Sessions.aspx?View=Sessions_summary&ID=723 In addition to the conference’s wide array of expert speakers and industry thought leaders, the summit will also play host to hundreds of exhibitors set to feature some of the industry’s latest innovations, products, and services. Attendees will also be able to participate in an industry networking event, “Back-to-Business Celebration”, which will be held immediately post the first day of the CWCBExpo, wherein conference delegates will be able to network and further their interactions with their fellow peers. For more information about the CWCBExpo, visit https://cwcbexpo.com/

• U.S.-based FingerMotion is a communications technology services company focused on the enormous Chinese consumer base and its adoption of mobile devices
• FingerMotion has established its operations on a stable tripod of services including SMS, MMS, and big data technologies
• The company recently reported growing revenues derived primarily from its SMS and MMS products
• On Oct. 25 the company introduced two new brands for value-added services that will help underwrite protection plans for mobile devices during the coming year
• FingerMotion expects its big data platform Sapientus to eventually outstrip SMS and MMS revenues as it becomes a significant tool for establishing consumer risk predictive services for China’s 1.4 billion people

Communications technology company FingerMotion (OTCQX: FNGR) is establishing itself as a powerhouse in consumer access within China’s enormous mobile technology use population base. Building on its recently reported 25 percent YOY quarterly revenue growth from short and multimedia messaging (SMS and MMS) services (https://ibn.fm/zSohm), the company has added two brands that will pair with a large American insurance company to help with underwriting mobile device protection programs (https://ibn.fm/tDEub). FingerMotion’s trademarked big data platform, Sapientus, has gained attention because of its unparalleled access to China’s consumers, handling over half a million transactions daily for its mobile payment and recharge services while providing the foundation for an insurtech industry capable of analyzing insurance and credit risks in a market where credit scoring infrastructure is not as developed as in the United States. Global insurer Pacific Life reached an agreement with FingerMotion earlier this year that effectively positions FingerMotion as the data provider for Pacific Life’s Re-insurance division (https://ibn.fm/sD9On). SMS functions such as mobile texting, MMS functions such as photo and video sharing, and big data analysis for Sapientus’ algorithm clients provide the three tripod legs sustaining FingerMotion’s business model and its sphere of innovation. The newest brands are trademarked as Ji Shi Fu and Baowo under FingerMotion’s subsidiary Shanghai JiuGe Information Technology Co., Ltd. The brands are expected to provide value-add services by covering mobile consumer maintenance needs such as broken phone screens, accidental damage repairs and compensation, and older device trade-in’s. The company states the services will come online early next year and could generate new revenue channels from more than 10 of China’s provinces, beginning with beta testing this month in Shanghai, Guangdong, Anjui, Zhejiang, and Henan provinces. “This latest development demonstrates the flexibility of our business model to explore ways to monetize our vast active user base,” CEO Martin Shen stated in the company’s news release. China has become a sought-after market as companies have established footholds for the businesses internationally, primarily because of China’s world-leading population, which is expected to top 1.4 billion this year. The country is developing one of the world’s fastest growing economies and is increasingly accessible to outside interests. FingerMotion expects its existing unique opportunity to collect and store big data for the Chinese economy and convert it into something actionable for end users without having to expend great sums in marketing and consumer retention will continue to grant it an attractive investment profile. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex
• The study will also compare DehydraTECH-CBD to generic CBD
• EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022
• Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents

Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://ibn.fm/LG7O6). EPIL-A21-1, which will be conducted by a talented team that includes respirology and neurology experts, will explore whether DehydraTECH-processed cannabidiol (“CBD”) evidences similar or superior efficacy in reducing or inhibiting seizure activity compared to Epidiolex, which is now sold by Jazz Pharmaceuticals (“Jazz”) subsequent to the 2021 US$7.2 billion takeover of GW Pharmaceuticals plc by Jazz. The study will also compare DehydraTECH-CBD to generic CBD. With laboratory studies, research reports, and anecdotal evidence suggesting that CBD could potentially control seizures, and results from clinical trials involving Epidiolex – now the first FDA-approved CBD-based drug for the treatment of seizures associated with two rare and severe forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome – indicating the advantageous effects of CBD in treating treatment-resistant seizure disorders, this non-psychoactive component of marijuana represents hope for patients who have been resistant to conventional anti-seizure drugs (https://ibn.fm/6NQ5E). Through previous human and animal studies, Lexaria has evidenced that DehydraTECH improves the speed of onset is more effective at delivering CBD into the bloodstream, and increases brain absorption of CBD. Having already shown success with CBD, Lexaria believes the DehydraTECH technology could potentially improve therapeutic efficacy for a range of disease conditions affecting the central nervous system, including epilepsy, hence the EPIL-A21-1 study. The study is being conducted by a leading US-based independent laboratory using advanced DehydraTECH 2.0 formulations and has entered early-stage preparatory work. Results are expected by Q3 2022. Elsewhere, Lexaria, which as of September of 2021 had 21 issued patents and more than 50 pending patent applications globally (https://ibn.fm/i2Ku2), recently announced it had received its first patent award for DehydraTECH in Mexico and another in Japan. The patent award in Mexico safeguards the proprietary technology for use with cannabinoids and nicotine, while the patent in Japan is for the use of DehydraTECH with non-psychoactive cannabinoids, vitamins, nicotine, or non-steroidal anti-inflammatory (“NSAID”) substances. These are two of the five patents that have been awarded to Lexaria in 2021.  The pair also strengthen the company’s IP portfolio with a collection that now includes 23 granted patents covering multiple countries. Lexaria is a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble APIs and drugs through its proprietary drug delivery technology, DehydraTECH. The technology pairs APIs with fatty acids such as long-chain fatty acid before applying the resulting combination to carrier particles like gum Arabic or sorbitol. The product then undergoes a dehydration synthesis procedure before being rendered for use in the desired final form factor. Through this proprietary and revolutionary technology, Lexaria makes it possible to deliver bioactive substances via oral ingestion without the need for unhealthy, deleterious practices of inhalation dosing, as is the case with nicotine, and without the need for co-administration with harmful sugars or sweeteners commonly used to mask bitter tastes. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Cannabis Strategic Ventures’ 2020 revenue jumped 517% year-over-year to $14.6 million
• 2020 revenues from cannabis sales were $14.1 million, up 975% compared to fiscal 2019
• The company’s gross profit spiked 483% year-over-year, reaching $2.78 million in 2020, while gross margins held steady at about 20 percent
• Cannabis Strategic Ventures will launch its first Los Angeles dispensary in Q4 2021
• The company will open an indoor cultivation facility with capacity to produce up to 15,000 pounds of premium cannabis flower annually

Cannabis Strategic Ventures (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration. Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually. Brand Portfolio The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands. The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis. MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability. Market Outlook The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market. According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025. According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.” Management Team Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California. For more information, visit the company’s website at www.CannabisStrategic.com. NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://ibn.fm/NUGS

• Since the 19^th century, average global temperatures have increased by over 2 degrees Fahrenheit
• Since 1971, climate change has slowed down the growth in agricultural productivity by about a fifth as a result of human activity
• It is estimated that the transportation, energy and food sectors alone can directly eliminate over 90% of net greenhouse gas (“GHG”) emissions worldwide in just 15 years
• FuelPositive, through its modular and scalable carbon-free ammonia system, is offering a solution that cuts across these three sectors, ultimately reducing GHG emissions
• With its technology, the company is defining the ongoing disruption within these sectors and laying down the foundation of what the future could look like

A recent study from Cornell University revealed that since 1971, climate change, as a result of human activity, has slowed down the growth in agricultural productivity by about a fifth (https://ibn.fm/YuCV3). This study further noted that the sensitivity of agricultural productivity increases as temperatures rise, meaning that each additional fraction of a degree is more detrimental to food production than the last. The planet today is experiencing overall temperatures that are higher than ever and continues to warm as time progresses. Since the 19^th century, average temperatures have increased by over 2 degrees Fahrenheit, with the trend persisting and perhaps accelerating (https://ibn.fm/HwV3a). Agriculture is not the only affected sector. The energy sector has also fallen victim to climate change. As of 2019 in the United States, most of the country’s electricity was generated by natural gas, followed by coal and nuclear energy. Renewable sources such as hydropower, wind, geothermal, biomass, and solar power generate only 17% of the country’s electricity (https://ibn.fm/B0WEZ). With the mounting pressure to ditch coal, coupled with climate change and its impact on hydropower, the government is being forced to look for more sustainable alternative energy production and storage solutions. FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is a company that is committed to clean energy solutions. It understands the impact of global warming and climate change. It is, as such, at the forefront of offering a sustainable solution that cuts across the energy, transportation and food sectors. Through its carbon-free ammonia, available for use in a variety of applications, FuelPositive is confident that it can help to significantly reduce CO2 emissions and offer long-term storage of excess electricity for energy grids. Combined, the application to the transportation, energy and food sectors alone could directly eliminate over 90% of net greenhouse gas (“GHG”) emissions worldwide in just 15 years. Market experts have even pointed out that market forces can be tapped to push the bulk of global GHG emissions mitigation, mainly since the technologies required are either already commercially available and competitive today or can be deployed to the market by 2025 (https://ibn.fm/ILy0e). FuelPositive’s carbon-free ammonia is a solution that make a significant difference in the near future — as early as 2022. It is a solid and sustainable solution that can help mitigate the global GHG emissions, and it cuts across these three key sectors. For agriculture, the company’s carbon-free ammonia can eliminate fertilizer-related carbon emissions, reducing the overall carbon footprint and the accompanying GHG emissions in this sector (https://ibn.fm/pu2Pn). As for transportation, FuelPositive’s solution can provide an affordable, convenient and sustainable supply of hydrogen for fuel cells. Alternatively, research has proven that carbon-free ammonia can be used on its own as a fuel. Planes, trains, trucks, ships, and even small vehicles can be easily converted to run on ammonia, just as easily as they can be converted from gasoline and diesel to run on propane (https://ibn.fm/Z88Sk). As for energy generation, FuelPositive’s carbon-free ammonia is the perfect catalyst that will enable the shift to a hydrogen economy. As well, it offers easy long-term storage of excess electricity for energy grids while also making it easy to provide electricity to northern or remote communities (https://ibn.fm/Hzn4t). This is mainly attributed to several key factors associated with ammonia. For one, FuelPositive’s carbon-free ammonia requires 30% less energy than conventional ammonia production, with zero carbon emissions. Secondly, it stores 65% more hydrogen than highly compressed hydrogen while keeping costs low from start to finish (https://ibn.fm/d3Opd). The carbon-free ammonia is also easy to produce and store on site, making it a suitable energy source for individuals and communities living in remote areas. With the ongoing climate change problem, there is a growing need to remedy the situation. The three sectors — energy, transportation and the food sectors — have been marked as key contributors to this change and key areas that need to be addressed if the issue is to be fixed. FuelPositive understands this urgency, hence its focus on these sectors and offering a solid solution with its carbon-free ammonia. Through its modular and scalable technology, the company is defining the ongoing disruption within these sectors and laying down the foundation of what the future will look like. Its technology and solutions have been tried and tested, and with it, net greenhouse gas emissions will reduce in the coming years. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF